SCHEMBL11031933

SCHEMBL11031933

COc1cccc(Cc2cnc(C(N)=O)c(Nc3ccc(N4CCN(C)CC4)cc3)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK2 P49137 1/20 0.51
▸ VNN1 O95497 1/20 0.51
▸ STAT6 P42226 2/20 0.51
▸ JAK2 O60674 2/20 0.49
▸ EGFR P00533 2/20 0.49
▸ PTK2 Q05397 2/20 0.49
▸ BRD4 O60885 2/20 0.48
▸ AURKA O14965 1/20 0.47
▸ CDK4 P11802 1/20 0.47
▸ ERBB3 P21860 1/20 0.47
▸ SLC2A1 P11166 2/20 0.47
▸ CSF1R P07333 1/20 0.47
▸ SYK P43405 1/20 0.47
▸ FGFR3 P22607 1/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ USP2 O75604 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11028483 0.90 EGFR (0.49) MAPKAPK2VNN1STAT6JAK2EGFR
SCHEMBL11030519 0.88 MAPKAPK2 (0.49) MAPKAPK2STAT6JAK2EGFRPTK2
SCHEMBL11025081 0.88 STAT6 (0.55) MAPKAPK2STAT6EGFRPTK2AURKA
SCHEMBL11029481 0.88 SLC2A1 (0.52) MAPKAPK2STAT6JAK2EGFRPTK2
SCHEMBL11028029 0.88 CDK4 (0.53) MAPKAPK2STAT6EGFRPTK2AURKA
SCHEMBL11029564 0.86 TNIK (0.52) STAT6EGFRPTK2AURKACDK4
SCHEMBL11029790 0.85 MAPKAPK2 (0.52) MAPKAPK2STAT6EGFRPTK2SLC2A1
SCHEMBL11027457 0.84 CDK2 (0.50) STAT6JAK2EGFRPTK2BRD4
SCHEMBL11029543 0.83 MAPKAPK2 (0.49) MAPKAPK2STAT6EGFRAURKACDK4
SCHEMBL11030740 0.83 SLC2A1 (0.55) MAPKAPK2STAT6JAK2EGFRPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 MAPKAPK2 115/4885VNN1 3589/4885STAT6 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback